Reliant Adds Antara To Cardiovascular Portfolio Following Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Antara (fenofibrate) clears FDA under Sec. 505(b)(2) NDA provision; it will compete with Abbott's Tricor to treat adult patients with primary hypercholesterolemia, mixed dyslipidemia, or hypertriglyceridemia. Abbott is developing a new formulation of Tricor.